Abstracts Archive - Page 217 of 2425 - ACR Meeting Abstracts

Abstract Number: 0787 • ACR Convergence 2023
Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry
Kristina Clark¹, Shiwen Xu², Voon Ong³, Christopher Buckley⁴ and Christopher Denton², ¹Barts Health NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: We previously described distinct migratory and resident fibroblast populations from lesional skin biopsies in SSc patients. Both populations are profibrotic compared with those from…
Abstract Number: 0724 • ACR Convergence 2023
Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model
Richard Bell, Ewurama Cann, Chao Yang, Accelerating Medicine Partnership Rheumatoid Arthritis, Amit Lakhanpal, Laura Donlin and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq has defined…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
Abstract Number: 0765 • ACR Convergence 2023
RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives
Guy Katz¹, Melissa Briones², Nina Couette³, Meridith Balbach⁴, Sabahat Usmani⁵, Lauren He⁶, Michael Macklin⁶, Iman Qaiser⁷, John Kellogg⁸, Courtney Bair⁸, Benjamin Lueck⁸, Akrithi Garren⁹, Matthew Sparks⁸, Lisa Criscione-Schreiber⁸ and David Leverenz⁸, ¹Massachusetts General Hospital, Boston, MA, ²Loyola University, Maywood, IL, ³Genesis Healthcare System, Columbus, OH, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶University of Chicago, Chicago, IL, ⁷Louisiana State University, Shreveport, LA, ⁸Duke University School of Medicine, Durham, NC, ⁹MedStar/Georgetown Washington Hospital Center, Silver Spring, MD
Background/Purpose: RheumMadness is an online tournament of rheumatology concepts that has been shown to engage learners using the Community of Inquiry (CoI) framework. theMednet is…
Abstract Number: 0362 • ACR Convergence 2023
Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis
Danielle Bullock¹, Ilir Agalliu², Evin Rothschild², Kaveh Ardalan³, Erica Lawson⁴, Natoshia Cunningham⁵, William Soulsby⁴, Nicole Reitz⁶, Laura Bouslaugh⁷, Anna Diggs⁸, Elizabeth Kessler⁹, Sara Kramer¹, Bhupinder Nahal⁴, Cassandra Davis¹⁰, Ashley Kemp¹, Riley O'Connor¹, Tiffany Chinn⁴, Kathy Nguyen⁴, Paige Hill¹ and Tamar Rubinstein¹¹, ¹University of Minnesota, Minneapolis, MN, ²Albert Einstein College of Medicine, Bronx, NY, ³Duke University School of Medicine, Durham, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Michigan State University, Grand Rapids, MI, ⁶CARRA, Allendale, MI, ⁷CARRA, Washington, DC, ⁸CARRA, Tipton, MO, ⁹Spectrum Health, Grand Rapids, MI, ¹⁰University of Utah, Salt Lake City, UT, ¹¹Albert Einstein College of Medicine, Children's Hospital at Montefiore, White Plains, NY
Background/Purpose: Adverse childhood events (ACEs) are common in children. ACEs are various stressors, including, but not limited to parental incarceration or food and housing insecurity.…
Abstract Number: 0593 • ACR Convergence 2023
Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Pablo Navarro³, Javier Loricera⁴, Angel Garcia-Aparicio⁵, Carmen Lasa⁶, Vanesa Calvo Río⁷, Adela Gallego⁸, Clara Moriano Morales⁹, Javier Narvaez¹⁰, MARIA IRENE CARRION BARBERA¹¹, Jordi Camins-Fàbregas¹², Joaquin Maria Belzunegui Otano¹³, Ana Urruticoechea¹⁴, Leticia del Olmo Perez¹⁵, Santos Castañeda¹⁶, Patricia Quiroga¹⁶, Ivette Casafont-Sole¹⁷, Juan Ramon De Dios Jimenez De Aber¹⁸, Marta López¹⁹, Judit Font Urgelles²⁰, Rafaela Ortega Castro²¹, Marta Garijo Bufort²², Jorge Juan Fragio²³, Ignacio Vázquez²⁴, Mamen Ortega²⁵, Aaron Fariñas²⁶, Cilia Peralta²⁷, Juan María Blanco²⁸, Sergi Heredia Martin²⁹, Maria Valvanera Pinillos³⁰, Eztizen Labrador-Sánchez³¹, Piter Jose Cossio Jimenez³², Carlos Vazquez Galeano³³ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Rheumatology, Hospial Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario de Toledo, Toledo, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁷Valdecilla Hospital, Santander, Spain, ⁸Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital General de Granollers, Granollers, Spain, ¹³University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁴Hospital Can Misses, Ibiza, Spain, ¹⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ¹⁶Hospital Universitario de la Princesa, Madrid, Spain, ¹⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital de Araba, Alava, Spain, ¹⁹Hospital Universitario Arava, Pamplona, Spain, ²⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ²¹Hospital Reina Sofía, Cordoba, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Hospital General Universitario Valencia, Valencia, Spain, ²⁴H. U. Dr. Peset, Valencia, Spain, ²⁵Hospital Universitario de Getafe, Getafe, Spain, ²⁶Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁷Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁸Hospital Universitario de Basurto, Bilbao, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰Hospital Universitario San Pedro, Logroño, Spain, ³¹Hospital Universitario San Pedro, Laguardia, Spain, ³²HOSPITAL REINA SOFIA, Tudela, Spain, ³³ZARAGOZA, Madrid, Spain
Background/Purpose: Belimumab (BLM) is a B-cell stimulating factor (BlyS) monoclonal antibody, approved in 2022 for the treatment of lupus nephritis (NL) and since 2011 for…
Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Brad Rovin¹, Jorge Ross Terres², Sophia Giang³, Thomas Schindler⁴, Armando Turchetta⁵, Jay Garg², Richard Furie⁶, William F. Pendergraft III² and Ana Malvar⁷, ¹Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Genentech, Inc., San Francisco, CA, ⁴F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶Northwell Health, Manhasset, NY, ⁷Hospital Fernandez, Buenos Aires, Argentina
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
Abstract Number: 0767 • ACR Convergence 2023
Current Musculoskeletal Ultrasound Practices of 12 Years of past Participants of a 10-Months Rheumatology Ultrasound Training Program (Ultrasound School of North American Rheumatologists)
Midori Nishio¹, Fawad Aslam², Sonja Ziniel³ and Eugene Kissin⁴, ¹John Muir Specialty Medical Group, Walnut Creek, CA, ²Mayo Clinic, Arizona, Scottsdale, AZ, ³Univ of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, CO, ⁴Boston University, Newton, MA
Background/Purpose: Musculoskeletal ultrasound (MSKUS) is an integral part of rheumatology training. The Ultrasound School of North American Rheumatologists (USSONAR) has been a leader in rheumatology…
Abstract Number: 0575 • ACR Convergence 2023
The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice
Andrew Concoff¹, Laura Moore-Schiltz², Vijay Nadipelli³, Tyler O'Malley¹, Karen Worley⁴, Allison Petrilla², Debra Zach¹, Scott B. Robinson², Sara Taiyari⁵, Barton Jones² and Bernard Rubin⁶, ¹Exagen, Vista, CA, ²Inovalon, Bowie, MD, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ⁵GlaxoSmithKline, Collegeville, PA, ⁶GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Patients with active SLE have periods of uncontrolled disease activity that are associated with a greater risk for developing irreversible organ damage. Current standard…
Abstract Number: 0782 • ACR Convergence 2023
Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies
Maria Dall'Era¹, Ernie Yap², Matt Truman², Lucy Hodge² and Neil Solomons³, ¹University of California San Francisco, San Francisco, CA, ²Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ³Neil Solomons Consulting Inc., Victoria, BC, Canada
Background/Purpose: Dual-immunosuppressive regimens consisting of high-dose glucocorticoids and higher doses ( >2 g/day) of mycophenolate mofetil (MMF) are still frequently used for the initial management…
Abstract Number: 0363 • ACR Convergence 2023
Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort
Michael Matt¹, Daniel Drozdov¹, Rolla Abu-Arja², Shanmuganathan Chandrakasan³, Kyla Driest², Elvira Cannizzaro Schneider⁴, Despina Moshous⁵, Benedicte Neven⁵, Karen Onel⁶, Sampath Prahalad⁷, Susan Prockop⁸, Pierre Quartier⁵, Johannes Roth⁹, Donna Wall¹⁰, Ulrike Zeilhofer¹¹, Scott Canna¹², Alexei Grom¹, Grant Schulert¹ and Rebecca Marsh¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Emory University School of Medicine, Atlanta, GA, ⁴Universitaetskinderspital Zurich, Zurich, Switzerland, ⁵Paris Cité Université and Necker Hospital, Paris, France, ⁶Hospital for Special Surgery, New York, NY, ⁷Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, ⁸Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children's Hospital of Zurich, Zurich, Switzerland, ¹²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Refractory systemic juvenile idiopathic arthritis (sJIA) in children can be complicated by repeated episodes of macrophage activation syndrome (MAS) or sJIA-related lung disease (sJIA-LD).…
Abstract Number: 0402 • ACR Convergence 2023
Automated Detection and Quantification of Hand Joint Swelling in Rheumatoid Arthritis: Computer Vision, Deep Neural Network Models, and a Potential Biomarker for Disease Activity Monitoring
Marc Blanchard¹, Jules Maglione², Cinja Koller³, Patrick Hermann⁴, David Brüschweiler³, Arnd Kleyer⁵ and Thomas Hügle⁶, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²EPFL, Lausanne, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴ATREON SA, Lausanne, Switzerland, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: We have previously shown that automated detection and processing of dorsal finger fold patterns from hand photographs can be used as a digital biomarker…
Abstract Number: 0597 • ACR Convergence 2023
Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Withrop⁷, Ihor Hupka⁸, Micki Hultquist⁹, Raj Tummala⁹, Gabriel Abreu¹⁰, Catharina Lindholm¹⁰ and Hussein Al-Mossawi¹¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁸BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland, ⁹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹⁰BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE is a systemic autoimmune disease requiring long-term treatment. In this placebo-controlled phase 3 TULIP long-term extension (LTE) study,1 the impact of anifrolumab in…
Abstract Number: 0735 • ACR Convergence 2023
Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis
Jun Inamo¹, Joshua Keegan², Alec Griffith², Tusharkanti Ghosh³, Alice Horisberger², Kaitlyn Howard², John Pulford², Ekaterina Murzin², Brandon Hancock², The Accelerating Medicines Partnership SLE/RA⁴, Marie Feser⁴, Jill Norri⁵, Anna Helena Jonsson⁶, Ye Cao⁷, William Apruzzese⁸, S. Louis Bridges⁹, Vivian Bykerk¹⁰, Susan Goodman⁹, Laura Donlin⁹, Gary S Firestein¹¹, Harris Perlman¹², Joan Bathon¹³, Laura Hughes¹⁴, Darren Tabechian¹⁵, Andrew Filer¹⁶, Costantino Pitzalis¹⁷, Jennifer Anolik¹⁵, Larry Moreland¹⁸, Joel Guthridge¹⁹, Judith James¹⁹, Michael Brenner², Soumya Raychaudhuri⁶, Jeffrey Sparks²⁰, Jennifer Seifert²¹, Michael Holer⁴, Kevin Deane⁴, James Lederer², Deepak Rao⁶ and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, University of California San Diego, La Jolla, CA, ¹²Northwestern University, Chicago, IL, ¹³Columbia University, New York, NY, ¹⁴University of Alabama at Birmingham Medicine, Birmingham, AL, ¹⁵University of Rochester Medical Center, Rochester, NY, ¹⁶University of Birmingham, Birmingham, United Kingdom, ¹⁷Queen Mary University of London, London, United Kingdom, ¹⁸University of Colorado, Denver, CO, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²¹The Accelerating Medicines Partnership RA/SLE Network, ²²University of Colorado, Aurora, CO

Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been used to investigate established RA heterogeneity…
Abstract Number: 0736 • ACR Convergence 2023
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics
Juan Vargas¹, Ian Mantel², Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao³, Susan Goodman⁵, Kevin Deane¹, The Accelerating Medicines Partnership SLE/RA¹, Jennifer Anolik⁶, Michael Brenner⁴, Soumya Raychaudhuri³, Jennifer Seifert⁷, Michael Holer¹, Laura Donlin⁵ and Fan Zhang⁸, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Weill Cornell Medicine, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶University of Rochester Medical Center, Rochester, NY, ⁷the Accelerating Medicines Partnership (AMP) RA/SLE Network, Boston, MA, ⁸University of Colorado, Aurora, CO

Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in autoimmune disease pathogenesis. In patients with rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].